DE69839326D1 - ZUSAMMENSETZUNGEN UND METHODEN ZUR MODULIERUNG DER ZELLULÄREN AKTIVITÄT VON NF-kappaB - Google Patents

ZUSAMMENSETZUNGEN UND METHODEN ZUR MODULIERUNG DER ZELLULÄREN AKTIVITÄT VON NF-kappaB

Info

Publication number
DE69839326D1
DE69839326D1 DE69839326T DE69839326T DE69839326D1 DE 69839326 D1 DE69839326 D1 DE 69839326D1 DE 69839326 T DE69839326 T DE 69839326T DE 69839326 T DE69839326 T DE 69839326T DE 69839326 D1 DE69839326 D1 DE 69839326D1
Authority
DE
Germany
Prior art keywords
compositions
modulating
kappa
methods
kappab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69839326T
Other languages
English (en)
Other versions
DE69839326T2 (de
Inventor
Anthony Manning
Frank Mercurio
Irit Alkalay
Yinon Ben-Neriah
Aaron Ciechanover
Avraham Yaron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Signal Pharmaceuticals LLC
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Signal Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem, Signal Pharmaceuticals LLC filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of DE69839326D1 publication Critical patent/DE69839326D1/de
Application granted granted Critical
Publication of DE69839326T2 publication Critical patent/DE69839326T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Mobile Radio Communication Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
DE69839326T 1997-02-18 1998-02-18 ZUSAMMENSETZUNGEN UND METHODEN ZUR MODULIERUNG DER ZELLULÄREN AKTIVITÄT VON NF-kappaB Expired - Lifetime DE69839326T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US802322 1997-02-18
US08/802,322 US5932425A (en) 1997-02-18 1997-02-18 Compositions and methods for modulating cellular NF-κB activation
PCT/US1998/003163 WO1998036070A1 (en) 1997-02-18 1998-02-18 COMPOSITIONS AND METHODS FOR MODULATING CELLULAR NF-λB ACTIVATION

Publications (2)

Publication Number Publication Date
DE69839326D1 true DE69839326D1 (de) 2008-05-15
DE69839326T2 DE69839326T2 (de) 2009-04-16

Family

ID=25183386

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69839326T Expired - Lifetime DE69839326T2 (de) 1997-02-18 1998-02-18 ZUSAMMENSETZUNGEN UND METHODEN ZUR MODULIERUNG DER ZELLULÄREN AKTIVITÄT VON NF-kappaB

Country Status (9)

Country Link
US (1) US5932425A (de)
EP (1) EP1009824B1 (de)
JP (2) JP4560616B2 (de)
AT (1) ATE391177T1 (de)
AU (1) AU6659198A (de)
CA (1) CA2281920C (de)
DE (1) DE69839326T2 (de)
HK (1) HK1028784A1 (de)
WO (1) WO1998036070A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU726383B2 (en) * 1996-08-26 2000-11-02 Signal Pharmaceuticals, Inc. Stimulus-inducible I (KAPPA)B kinase (IKK) signalsome
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
CA2650204A1 (en) 1996-12-31 1998-07-09 Harry B. Demopoulos Pharmaceutical preparations of glutathione and methods of administration thereof
EP1088100A2 (de) * 1998-06-13 2001-04-04 Zarpex Biosciences Limited Proteosomale wirksamkeit
ATE499445T1 (de) * 1998-12-10 2011-03-15 Signal Pharm Llc Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b
US6468755B1 (en) 1999-08-10 2002-10-22 Joslin Diabetes Center, Inc. Method for identifying compounds for treatment of insulin resistance
US6630312B2 (en) 1999-08-10 2003-10-07 Joslin Diabetes Center, Inc. Method for identifying compounds for treatment of insulin resistance
US20030104622A1 (en) * 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
FR2801902B1 (fr) * 1999-12-01 2005-03-04 Centre Nat Rech Scient Procedes de criblages fonctionnels d'agents aptes a moduler l'activite des complexes ubiquitine-ligases scf et leurs applications
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US20030044852A1 (en) * 2000-08-10 2003-03-06 Joslin Diabetes Center, Inc., A Massachusetts Corporation Methods for treatment of insulin resistance
US20060287337A1 (en) * 2001-11-09 2006-12-21 Proteologics, Inc. Trans-golgi network-associated processes, methods and compositions related thereto
WO2003048202A2 (en) * 2001-12-03 2003-06-12 Asahi Kasei Pharma Corporation Nf-kappab activating genes
FR2859733A1 (fr) * 2003-09-15 2005-03-18 Centre Nat Rech Scient Procede de criblage fonctionnel d'agents aptes a moduler l'activite des ubiquitine hydrolases et leurs applications
EP2261586B1 (de) * 2004-03-02 2017-07-19 The Procter & Gamble Company Verfahren zum härten von emulsionen mit hoher interner phase
FR2867783B1 (fr) * 2004-03-16 2008-02-01 Cytomics Systems Procede de criblage d'agent modulant l'ubiquitination de la proteine ikbalpha et moyens destines a la mise en oeuvre dudit procede
US20070060537A1 (en) * 2005-04-28 2007-03-15 Proteologics, Inc. Methods and compositions for inhibiting viral infections
US20100292306A1 (en) * 2005-05-24 2010-11-18 Carlson C George Compositions And Methods For The Treatment Of Muscular Dystrophy
US20070202593A1 (en) * 2006-02-27 2007-08-30 Research Development Foundation Cell-Targeted IKB and Methods for the Use Thereof
AR066016A1 (es) * 2007-04-11 2009-07-15 Alcon Res Ltd Uso de un inhibidor del tnf alfa junto con una antihistamina para tratar la rinitis alergica y la conjuntivitis alergica
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
WO2010044892A1 (en) 2008-10-17 2010-04-22 President And Fellows Of Harvard College Diagnostic method based on large scale identification of post-translational modification of proteins
CN102548536A (zh) * 2009-10-01 2012-07-04 爱尔康研究有限公司 奥洛他定组合物及其用途
KR20210110623A (ko) 2018-12-28 2021-09-08 리제너론 파마슈티칼스 인코포레이티드 아라키도네이트15-리폭시게나제 (alox15) 억제제를 사용하는 호흡기 장애의 치료

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122463A (en) * 1990-05-17 1992-06-16 Massachusetts Institute Of Technology Methods for trans-destabilization of specific proteins in vivo and dna molecules useful therefor
NZ257181A (en) * 1992-10-29 1997-07-27 Medical Res Council Transcription factor dp-1, dna, vectors and host cells therefor
DE4243770A1 (de) * 1992-12-23 1994-06-30 Behringwerke Ag Verfahren zur Herstellung von rekombinanten und synthetischen Peptiden und deren Verwendung
IL114615A0 (en) * 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
JPH11509085A (ja) * 1995-06-23 1999-08-17 テュラリク インコーポレイテッド インターロイキン−１レセプター関連プロテインキナーゼ及び検定
AU726383B2 (en) * 1996-08-26 2000-11-02 Signal Pharmaceuticals, Inc. Stimulus-inducible I (KAPPA)B kinase (IKK) signalsome

Also Published As

Publication number Publication date
WO1998036070A1 (en) 1998-08-20
CA2281920C (en) 2010-05-04
JP4560616B2 (ja) 2010-10-13
AU6659198A (en) 1998-09-08
EP1009824A1 (de) 2000-06-21
JP2010063461A (ja) 2010-03-25
CA2281920A1 (en) 1998-08-20
EP1009824B1 (de) 2008-04-02
DE69839326T2 (de) 2009-04-16
ATE391177T1 (de) 2008-04-15
HK1028784A1 (en) 2001-03-02
JP2001512319A (ja) 2001-08-21
US5932425A (en) 1999-08-03

Similar Documents

Publication Publication Date Title
DE69839326D1 (de) ZUSAMMENSETZUNGEN UND METHODEN ZUR MODULIERUNG DER ZELLULÄREN AKTIVITÄT VON NF-kappaB
DE69427869D1 (de) Botulinumtoxine zur behandlung von hyperhydrosis
DE69414471T2 (de) Dichtungsanordnung zur Einführung von chirurgischen Instrumenten
DE69522301T2 (de) Dichtungsanordnung zur Einführung von chirurgischen Instrumenten
DE69711067D1 (de) Antikonvulsiva zur verwendung bei der behandlung von amyotropischer lateralsklerose
ATE413386T1 (de) Ppar-gamma modulatoren
EA199800667A1 (ru) Новые фенантридины
TR199802676A2 (xx) T�m�rlerin, t�m�rle ilgili hastal�klar�n ve ka�eksinin tedavisi ve �nlenmesi i�in y�ntem.
ES2179355T3 (es) Derivados de tiazol utilizados como inhibidores de proteina quinasa c.
ATE255632T1 (de) Immortalisierung bzw. desimmortalisierung von zellen
DE59302269D1 (de) Mittel zur festigung der haare auf der basis von lignin oder ligninderivaten sowie dihydroxypropyllignin
DE69533704D1 (de) Bradykinin-antagonist peptide mit n-substituierten glycinen
DE69915310D1 (de) Methoden zur behandlung der salzabhängigen hypertonie
DE69527140T2 (de) Wirkstoff zur prävention oder behandlung von osteoporose
WO2000053774A3 (en) Metalloproteinases and methods of use therefor
ATE293254T1 (de) Modulierung von mlk- (multiple lineage kinase) proteinen
DE69943222D1 (de) Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b
DE69940980D1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
ATE228760T1 (de) Thrombininhibitoren
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
DE69738600D1 (de) Neuroaktive peptide
DE69739449D1 (de) Invasionsinhibitoren zur verwendung in der wundheilung und krebsbehandlung
DE68920525D1 (de) Verfahren zur Definierung der Anwendung von Fernsprechertasten.
DE69738945D1 (de) Rken
DE69825307D1 (de) Verwendung von protein h als zytostattischer wirkstoff

Legal Events

Date Code Title Description
8364 No opposition during term of opposition